This application requests aggregate funding for continuation of current programs in enzymology and chemistry of bioactivation. Human cytochrome P-450 enzymes will be purified, particularly those involved in known polymorphisms of drug oxidation. The proteins will be characterized and the related genes cloned and identified; nucleic acid probes will be used to identify the molecular basis of catalytic polymorphism in each case. Enzyme reconstitution and immunoinhibition techniques will be used to determine the specificity of individual enzymes for specific drugs and pro-carcinogens. Another aspect of the proposal involves elucidation of the chemistry involved in the activation of the carcinogens ethylene dibromide and trichloroethylene and the parasympathomimetic alkaloid slaframine. The interactions of the ethylene dibromide/glutathione half-mustard/thiiranium ion with any specific sites on DNA will be probed and the biological roles of individual adducts will be examined. The roles of hepatic cytochrome P-450 forms in acute toxicity of chemicals to hepatocyte-derived cultured cells will be probed by microinjection of proteins and possibly gene tranfection. Finally, we propose to continue our studies on the chemistry involved in catalysis of oxygenation by cytochrome P-450, utilizing mechanism-based inactivators and diagnostic substrate probes (particularly cyclopropylamines and dihydropyridines), model metalloporphyrins, and physical descriptions of rate processes. These studies should enhance our understanding of how chemicals are activated to dangerous species and the inter-individual variations in susceptibility to these agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
1R35CA044353-01
Application #
3479544
Study Section
(SRC)
Project Start
1987-09-30
Project End
1994-06-30
Budget Start
1987-09-30
Budget End
1988-06-30
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Kim, H-J; Lee, S-B; Guengerich, F P et al. (2007) Effects of N-terminal modification of recombinant human cytochrome P450 1A2 on catalytic activity. Xenobiotica 37:356-65
Velez-Cruz, Renier; Riggins, James N; Daniels, J Scott et al. (2005) Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry 44:3972-81
Guengerich, F Peter (2005) Principles of covalent binding of reactive metabolites and examples of activation of bis-electrophiles by conjugation. Arch Biochem Biophys 433:369-78
Kim, Donghak; Guengerich, F Peter (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27-49
Guengerich, F Peter; Krauser, Joel A; Johnson, William W (2004) Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. Biochemistry 43:10775-88
Guengerich, F Peter (2004) Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 36:159-97
Kim, Eun-Young; Kim, Joon-Sik; Kim, Min-Young et al. (2004) Non-specific inhibition of human cytochrome P450-catalyzed reactions by hemin. Toxicol Lett 153:239-46
Peter Guengerich, F; Chun, Young-Jin; Kim, Donghak et al. (2003) Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524:173-82
Guengerich, F Peter (2003) Activation of dihaloalkanes by thiol-dependent mechanisms. J Biochem Mol Biol 36:20-7
Yun, Chul-Ho; Lee, Hye Suk; Lee, Hee-Yong et al. (2003) Roles of human liver cytochrome P450 3A4 and 1A2 enzymes in the oxidation of myristicin. Toxicol Lett 137:143-50

Showing the most recent 10 out of 288 publications